Results 61 to 70 of about 8,272,866 (282)

Cumulative Number of Male and Female PWIDs Initiating Medication Assisted Treatment.

, 2013
Cumulative Number of Male and Female PWIDs Initiating Medication Assisted Treatment.
Yovin Ivo (426293), Barrot H. Lambdin (426286), R. Douglas Bruce (426287), Omar Ubuguy (426295), Olivia Chang (332208), Sophia Zamudio-Haas (426290), Amani Msami (426294), Frank Masao (426292), Cassian Nyandindi (426288), Sheryl McCurdy (426291), Jessie Mbwambo (426296), Norman Sabuni (426289)   +11 more
core   +1 more source

Neurocognitive, School‐Based, and Quality of Life Outcomes for Youth With Sickle Cell Disease and Thalassemia: A Scoping Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT The medical burdens of sickle cell disease (SCD) and transfusion‐dependent β‐thalassemia (TDT) are chronic and cumulative, even in children. Yet the effects expand beyond medications and healthcare visits due to their impacts on school attendance, academic performance, and peer engagement.
Mary Ann Etling, Hakim Tokhi, Alexander A. Boucher   +2 more
wiley   +1 more source

Impact of recent methamphetamine use on treatment outcomes among individuals initiating medications for opioid use disorders in rural treatment settings: a 1-year retrospective cohort study

Rural and Remote Health
Introduction: Rates of N-methylamphetamine (methamphetamine) use in rural areas of the US have been steadily increasing, particularly among individuals who are already struggling with opioid use disorder.
Leslie Kenefick, Lisa Khairy, Luke Hall, Kibeom Kwon, Nicole Limberg, Kirsi Kirk-Lewis, Megan Lewis, Matt Owen, Sterling McPherson, Andre Miguel   +9 more
doaj   +1 more source

Advancing the implementation and sustainment of medication assisted treatment for opioid use disorders in prisons and jails

Health & Justice, 2019
Background Opioid use disorder (OUD) is among the most prevalent medical condition experienced by incarcerated persons, yet medication assisted therapy (MAT) is uncommon.
Warren J. Ferguson, Joan Johnston, Jennifer G. Clarke, Peter J. Koutoujian, Kathleen Maurer, Colleen Gallagher, Julie White, Dyana Nickl, Faye S. Taxman   +8 more
doaj   +1 more source

Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial

Implementation Science, 2017
Background Overdoses due to non-medical use of prescription opioids and other opiates have become the leading cause of accidental deaths in the USA.
Todd Molfenter, Hannah K. Knudsen, Randy Brown, Nora Jacobson, Julie Horst, Mark Van Etten, Jee-Seon Kim, Eric Haram, Elizabeth Collier, Sanford Starr, Alexander Toy, Lynn Madden   +11 more
doaj   +1 more source

Auricular neural stimulation as a new non-invasive treatment for opioid detoxification

Bioelectronic Medicine, 2020
The recent opioid crisis is one of the rising challenges in the history of modern health care. New and effective treatment modalities with less adverse effects to alleviate and manage this modern epidemic are critically needed.
Imran S. Qureshi, Timir Datta-Chaudhuri, Kevin J. Tracey, Valentin A. Pavlov, Andrew C. H. Chen   +4 more
doaj   +1 more source

Systematic content analysis of patient evaluations of START NOW psychotherapy reveals practical strategies for improving the treatment of opioid use disorder

BMC Psychiatry, 2021
Background Clinical trials provide consistent evidence for buprenorphine’s efficacy in treating opioid use disorder (OUD). While the Drug Addiction Treatment Act of 2000 requires physicians to combine medication-assisted treatment (MAT) with behavioral ...
Albert Yi-Que Truong, Brian Fabian Saway, Malek H. Bouzaher, Mustafa Nawroz Rasheed, Sanaz Monjazeb, Soleille Dorothy Everest, Susan Linda Giampalmo, David Hartman, Cheryl Hartman, Anita S. Kablinger, Robert L. Trestman   +10 more
doaj   +1 more source

Medication-assisted treatment for opioid addiction: Methadone and buprenorphine

Journal of Food and Drug Analysis, 2013
Among agents for treatment of opioid addiction, methadone is a full mu-opioid receptor agonist, whereas buprenorphine is a partial agonist. Both are long-acting. Buprenorphine has a superior safety profile. Methadone is formulated for oral administration and buprenorphine for sublingual administration.
Saxon, Andrew J, Hser, Yih-Ing, Woody, George, Ling, Walter   +3 more
openaire   +4 more sources

Client Flow from Outreach to Enrollment into Medication Assisted Treatment (MAT).

, 2013
Client Flow from Outreach to Enrollment into Medication Assisted Treatment (MAT).
Yovin Ivo (426293), Barrot H. Lambdin (426286), R. Douglas Bruce (426287), Omar Ubuguy (426295), Olivia Chang (332208), Sophia Zamudio-Haas (426290), Amani Msami (426294), Frank Masao (426292), Cassian Nyandindi (426288), Sheryl McCurdy (426291), Jessie Mbwambo (426296), Norman Sabuni (426289)   +11 more
core   +1 more source

What influences clinicians’ decisions about ADHD medication? Initial data from the "influences on prescribing for ADHD questionnaire" (IPAQ) [PDF]

, 2013
Despite evidence for its efficacy and effectiveness, the use of medication for the treatment of ADHD remains controversial. Little is known about the factors that influence clinicians’ decisions to use medication for ADHD.
Thompson, Margaret, Yardley, Lucy, Hodgkins, Paul, Barke, Edmund, Vrijens, May, Danckaerts, Marina, Sonuga-Barke, E, Kovshoff, Hanna   +7 more
core   +1 more source